Polycyclic nitrogen heterocycles as potential thymidine phosphorylase inhibitors: synthesis, biological evaluation, and molecular docking study.
Cell Line
Cell Survival
/ drug effects
Dose-Response Relationship, Drug
Enzyme Inhibitors
/ chemical synthesis
Heterocyclic Compounds
/ chemical synthesis
Humans
Molecular Docking Simulation
Molecular Structure
Nitrogen
/ chemistry
Polycyclic Compounds
/ chemical synthesis
Structure-Activity Relationship
Thymidine Phosphorylase
/ antagonists & inhibitors
Thymidine phosphorylase inhibitor
molecular docking
multicomponent reactions
pyrido[2,3-d]pyrimidinedione
pyrimido[4,5-b]quinoline-2,4-dione
Journal
Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
22
12
2021
pubmed:
23
12
2021
medline:
3
3
2022
Statut:
ppublish
Résumé
New polycyclic heterocycles were synthesised and evaluated as potential inhibitors of thymidine phosphorylase (TP). Inspired by the pharmacophoric pyrimidinedione core of the natural substrate, four series have been designed in order to interact with large empty pockets of the active site: pyrimidoquinoline-2,4-diones (series A), pyrimidinedione linked to a pyrroloquinoline-1,3-diones (series B and C), the polycyclic heterocycle has been replaced by a pyrimidopyridopyrrolidinetetraone (series D). In each series, the tricyclic nitrogen heterocyclic moiety has been synthesised by a one-pot multicomponent reaction. Compared to
Identifiants
pubmed: 34933639
doi: 10.1080/14756366.2021.2001806
pmc: PMC8725971
doi:
Substances chimiques
Enzyme Inhibitors
0
Heterocyclic Compounds
0
Polycyclic Compounds
0
TYMP protein, human
EC 2.4.2.4
Thymidine Phosphorylase
EC 2.4.2.4
Nitrogen
N762921K75
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
252-268Références
J Med Chem. 1994 Mar 4;37(5):674-88
pubmed: 8126708
Eur J Med Chem. 2016 Nov 29;124:992-1003
pubmed: 27783978
J Am Chem Soc. 1973 Apr 4;95(7):2320-4
pubmed: 4709235
Biochem Biophys Res Commun. 2009 Sep 4;386(4):666-70
pubmed: 19555658
Cancer Sci. 2004 Nov;95(11):851-7
pubmed: 15546501
Biochem J. 2006 Oct 15;399(2):199-204
pubmed: 16803458
J Chem Soc. 1947 Jun;:726-34
pubmed: 20259114
Biochem Pharmacol. 2000 May 15;59(10):1227-36
pubmed: 10736423
FEBS Lett. 1998 Oct 30;438(1-2):91-5
pubmed: 9821965
Br J Cancer. 2011 Mar 29;104(7):1185-92
pubmed: 21386840
J Biol Chem. 1990 Aug 15;265(23):14016-22
pubmed: 2199449
Br J Cancer. 2005 May 9;92(9):1696-701
pubmed: 15841086
Biochemistry (Mosc). 2007 Jan;72(1):21-8
pubmed: 17309433
J Med Chem. 2003 Nov 6;46(23):5045-54
pubmed: 14584954
Bioorg Med Chem. 2009 Apr 15;17(8):2983-8
pubmed: 19329330
Structure. 2004 Jan;12(1):75-84
pubmed: 14725767
N Engl J Med. 1991 Jan 3;324(1):1-8
pubmed: 1701519
J Am Chem Soc. 1968 Dec 18;90(26):7302-23
pubmed: 5725550
Bioorg Med Chem. 2004 Jul 1;12(13):3443-50
pubmed: 15186830
J Exp Med. 1971 Feb 1;133(2):275-88
pubmed: 4332371
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Bioorg Med Chem. 2004 Jul 1;12(13):3431-41
pubmed: 15186829
J Med Chem. 2006 Dec 28;49(26):7807-15
pubmed: 17181163
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):97-100
pubmed: 27668054
Cancer Microenviron. 2016 Apr;9(1):33-43
pubmed: 26298314
Mol Divers. 2010 Feb;14(1):123-30
pubmed: 19452259
Acta Crystallogr D Biol Crystallogr. 2014 Apr;70(Pt 4):1155-65
pubmed: 24699659
Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266
pubmed: 29338550
Mini Rev Med Chem. 2005 Dec;5(12):1113-23
pubmed: 16375757
Cancer Res. 1999 Apr 15;59(8):1911-6
pubmed: 10213500
Lancet. 2016 Jul 30;388(10043):518-29
pubmed: 26853587
Org Lett. 2002 Sep 19;4(19):3187-9
pubmed: 12227745
Cancer Res. 2000 Oct 1;60(19):5345-8
pubmed: 11034068
Med Res Rev. 2009 Nov;29(6):903-53
pubmed: 19434693